Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EpiATLAS - a reference for human epigenomic research.

bioRxiv : the preprint server for biology·2026
Same author

Does semicircular canal radiation increase the risk of new vestibulopathy after Gamma Knife radiosurgery for vestibular schwannoma?

Journal of neuro-oncology·2026
Same author

Socioeconomic status and outcomes following spine stereotactic body radiation therapy.

Journal of neuro-oncology·2026
Same author

Legalization of Cannabis Effect on Pediatric Edible Cannabis Exposures 2017-2022.

Clinical pediatrics·2026
Same author

Pediatric Hemp-Derived Cannabinoid and Δ9-Tetrahydrocannabinol Exposures: A National Poison Data Study.

The Journal of pediatrics·2026
Same author

Physical Performance Impairment with Cannabis Consumption in Adults Over 12 Hours.

Journal of drug education·2026

Related Experiment Video

Updated: Feb 14, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Temozolomide-associated hypermutation in gliomas.

Serah Choi1, Yao Yu1, Matthew R Grimmer2

  • 1Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Neuro-Oncology
|February 17, 2018
PubMed
Summary

Temozolomide (TMZ) can cause hypermutation in low-grade gliomas, potentially leading to malignant transformation. This review explores the mechanisms, consequences, and clinical significance of TMZ-induced hypermutation in glioma patients.

More Related Videos

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

8.3K
Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes
08:12

Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes

Published on: November 1, 2011

20.4K

Related Experiment Videos

Last Updated: Feb 14, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

8.3K
Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes
08:12

Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes

Published on: November 1, 2011

20.4K

Area of Science:

  • Neuro-oncology
  • Cancer genomics
  • Chemotherapy research

Background:

  • Low-grade gliomas frequently recur and can transform into high-grade gliomas with poor prognosis.
  • Temozolomide (TMZ) efficacy in low-grade gliomas is less understood compared to glioblastomas.
  • TMZ treatment in specific low-grade gliomas can result in hypermutation, increasing malignancy.

Purpose of the Study:

  • To review the mechanisms and consequences of temozolomide-induced hypermutation in low-grade gliomas.
  • To discuss the clinical significance of TMZ-induced hypermutation and its impact on malignant transformation.
  • To explore the implications of hypermutation for future therapeutic interventions, including immunotherapy.

Main Methods:

  • Literature review of studies on temozolomide treatment in low-grade gliomas.
  • Analysis of genomic data from recurrent gliomas showing TMZ-induced hypermutation signatures.
  • Discussion of preliminary findings and hypotheses regarding TMZ's role in glioma progression.

Main Results:

  • A subset of isocitrate dehydrogenase-mutant, low-grade astrocytomas treated with TMZ exhibit extensive de novo mutations upon recurrence.
  • TMZ-induced hypermutation is hypothesized to contribute to malignant transformation, with variable latency.
  • Hypermutated gliomas present altered genomes offering potential for novel therapeutic strategies.

Conclusions:

  • TMZ-induced hypermutation is a critical factor in low-grade glioma recurrence and malignant progression.
  • Understanding TMZ's effects is crucial for balancing treatment benefits against risks of transformation.
  • Hypermutation in gliomas opens avenues for targeted therapies and immunotherapy.